• Bio-Rad Laboratories recently announced that MicroVal approved its EZ-Check Listeria spp. and Listeria monocytogenes detection kits, confirming they meet ISO 16140-2 standards for use in food products and environmental samples.
• This additional international validation, alongside earlier AOAC recognition, strengthens confidence in Bio-Rad’s food safety testing portfolio and its global regulatory credibility.
• We’ll now examine how this added MicroVal validation for Bio-Rad’s Listeria detection kits may influence the company’s broader investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Bio-Rad Laboratories Investment Narrative Recap

To own Bio Rad, you need to believe its mix of life science tools and clinical diagnostics can translate into steadier earnings over time, despite funding and reimbursement pressures. The new MicroVal approval for its Listeria kits reinforces Bio Rad’s regulatory credentials in food safety, but it is unlikely to shift the near term focus away from weak instrument demand and ongoing margin pressure as the key catalyst and risk.

The most relevant recent development alongside this news is Elliott Investment Management’s new activist stake, disclosed in May 2026, after a share price decline of over 70% from its late 2021 peak. Combined with continued share buybacks totaling about US$762.9 million since mid 2023, this activism could influence how management prioritizes higher growth, higher margin areas such as validated diagnostics and food safety testing within Bio Rad’s broader portfolio.

Yet beneath these validation wins, one risk that investors should be aware of is...

Bio-Rad Laboratories' narrative projects $2.7 billion revenue and $226.1 million earnings by 2029. This requires 1.2% yearly revenue growth and a $57.3 million earnings increase from $168.8 million today.

Uncover how Bio-Rad Laboratories' forecasts yield a $293.00 fair value, in line with its current price.

Exploring Other Perspectives

While consensus focuses on modest growth and margin pressure, the most optimistic analysts, who once modeled revenue at about US$2.8 billion and earnings near US$231 million by 2029, see faster adoption of advanced diagnostics as offsetting risks like rising integration costs and potential obsolescence, reminding you that views on Bio Rad’s trajectory can differ widely and may shift again as new validations like MicroVal are absorbed.

Explore 2 other fair value estimates on Bio-Rad Laboratories - why the stock might be worth just $283.71!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Bio-Rad Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.